Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Biologic treatment options such as tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis. Recent data suggest, however, that full and long-lasting responses to TNF inhibitors are limited because of the activation of the pro-...

Descripción completa

Detalles Bibliográficos
Autores principales: Silacci, Michela, Lembke, Wibke, Woods, Richard, Attinger-Toller, Isabella, Baenziger-Tobler, Nadja, Batey, Sarah, Santimaria, Roger, von der Bey, Ulrike, Koenig-Friedrich, Susann, Zha, Wenjuan, Schlereth, Bernd, Locher, Mathias, Bertschinger, Julian, Grabulovski, Dragan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966518/
https://www.ncbi.nlm.nih.gov/pubmed/26390837
http://dx.doi.org/10.1080/19420862.2015.1093266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966518/
https://www.ncbi.nlm.nih.gov/pubmed/26390837
http://dx.doi.org/10.1080/19420862.2015.1093266

Ejemplares similares